Pharma Capsules - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma Capsules
Brief pharmaceutical news items for January 2008.

Pharmaceutical Technology
Volume 32, Issue 1

Meissner Debuts Green Website

Meissner (Camarillo, CA) launched a new website called Green Docs at http://www.meissner.com/greendocs. Green Docs makes product inserts, which were previously printed, available on the Internet 24 hours a day. The implementation of Green Docs is part of Meissner's overall plan to become an environmentally friendly manufacturer. Meissner says that customers can help save more than one acre of forested land annually by accessing and downloading these e-documents. Green Docs provides information and guidance on such topics as product specifications, filter integrity testing, and proper product installation.

Acquisitions
Cambridge Major Labs Acquires ChemShop

Cambridge Major Laboratories (CML, Germantown, WI) acquired ChemShop (Weert the Netherlands), a European supplier of active pharmaceutical ingredient (API) development services. The newly combined company is one of the largest pharmaceutical-chemistry development organizations in the Western hemisphere, according to CML. The merged companies have 140 employees at three sites in the US and Europe. ChemShop was renamed Cambridge Major Laboratories Europe.

ChemShop has provided process development and manufacturing services to the pharmaceutical industry for nine years. All of ChemShop's management and personnel will continue to operate the business at the Weert facility, which includes research and development laboratories, kilo-laboratory suites, and a pilot plant. The ChemShop facility provides intermediates and APIs on scales from grams to hundreds of kilograms.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here